A SYSTEM FOR THE CONTINUOUS INFUSION OF ALPHA-CHLORALOSE ANESTHETIC

ROBERT E. VAN PATTEN
This report was prepared by the Environmental Medicine Division of the Biomedical Laboratory, Aerospace Medical Research Laboratories, Aerospace Medical Division, Wright-Patterson Air Force Base, Ohio. The work was performed in support of Project 722, "Biophysics of Flight." The apparatus described in this report was developed over the period from December 1964 to May 1965.

Acknowledgement is given to Mr. Gene Hyer of Aeronautical Systems Division, Deputy for Flight Test, Directorate of Maintenance Fabrication and Modification Division, for his invaluable assistance in the fabrication of the delicate components of the system.

This technical report has been reviewed and is approved.

J. W. HEIM, PHD
Technical Director
Biomedical Laboratory
Aerospace Medical Research Laboratories
The development of a system designed to permit semiautomatic and continuous infusion of the anesthetic agent alpha-chloralose to dogs is described. The apparatus was developed for use in studies of cardiovascular and renal functions under various environmental conditions. The device has proved to be practical and trouble-free and the simple design uses easily available materials.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>SECTION</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. INTRODUCTION.</td>
<td>1</td>
</tr>
<tr>
<td>II. SYSTEM REQUIREMENTS.</td>
<td>1</td>
</tr>
<tr>
<td>III. SYRINGE HEATING.</td>
<td>2</td>
</tr>
<tr>
<td>IV. CATHETER HEATING</td>
<td>4</td>
</tr>
<tr>
<td>V. CONCLUSIONS.</td>
<td>6</td>
</tr>
</tbody>
</table>

## LIST OF ILLUSTRATIONS

<table>
<thead>
<tr>
<th>FIGURE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. SYRINGE HEATING DEVICE</td>
<td>3</td>
</tr>
<tr>
<td>2. HEATED CATHETER</td>
<td>5</td>
</tr>
</tbody>
</table>
SECTION I
INTRODUCTION

The apparatus described in this report was developed to provide continuous alpha-chloralose anesthesia for dogs in the study of cardiovascular and renal functions under various environmental conditions.

The relative insolubility of alpha-chloralose in water or physiologic salt solutions at room temperature, and its relatively short duration of action have previously required that a heated solution be injected manually as frequently as every 10 minutes. These inconveniences may explain the agent's decreasing use for animal physiologic studies, even though its physiologic advantages over other agents have recently been reaffirmed.

SECTION II
SYSTEM REQUIREMENTS

A system for the semiautomatic continuous infusion of chloralose requires the following basic elements:

Constant Infusion
This requirement was met through the use of a constant infusion pump (lead screw type) fitted with simple adapter hardware designed to hold the 50 cc reservoir syringe and its heater.

Temperature Control-Syringe
This portion of the system requires a source of voltage for heating, some means of controlling heater voltage, and of monitoring the temperature of the syringe heater element, as well as adaptors to allow mounting the syringe/heater assembly to the pump.

Temperature Control-Catheter
Requirements generally the same as for the syringe, involving control and monitoring elements as well as provisions for connecting the catheter to the syringe.

Solution Replenishment
As the contents of the 50 cc syringe used in this system are exhausted, the chloralose solution must be replenished. This is accomplished by keeping a bulk solution heated and by transferring this solution via another syringe to the heated syringe. This is accomplished by uncoupling the driver plate of the pump (to free the syringe plunged) and introducing the new solution via a 3-way stopcock connected between the heated syringe and the heated catheter.

Approved for Public Release
SECTION III
SYRINGE HEATING

Figure 1 shows the essential portions of the device used to maintain a 50 cc syringe at a temperature sufficient to prevent precipitation of the chloralose solution. The central structure is a thin-walled aluminum tube with an internal diameter such that it provides a close slip fit with the syringe which will be used. Over this tube is wrapped a single layer of bakellite linen sheet, approximately 0.4 mm (0.016 inch) thick, fastened to the aluminum tube by a nonconducting commercial epoxy cement. The heater element composed of 20-gage nichrome wire is then wound (with the closest possible spacing that will avoid intercoil shorting) over the insulating bakellite sheath. After winding is completed, the coil is cemented in place with the same nonconducting epoxy cement used for the sheath. A copper constantan thermocouple was cemented in place on the mid-point of the coil to permit monitoring of the approximate heater temperature.

Following completion of this portion of the assembly, the heater unit was attached to the delivery end plate by press fitting and cementing it into a circular groove in the end plate. Note that the delivery end plate must be provided with an orifice large enough to permit passage of the end of the syringe to an accessible position.

The distal end of the heater element was secured to a screw terminal in the end plate (also made of bakellite) and a lead returned to the other end plate. The heater housing shell, consisting of a black anodized thin-walled aluminum cylinder was then fitted over the previous assembly, and the final end plate installed. Construction was completed by leading the thermocouple wires out and connecting the heater wires to a small commercial socket of suitable design.

In order to provide thermal and electrical insulation, the entire annular cavity of this assembly was filled completely with a commercial, liquid, room temperature, vulcanizing silicone rubber compound just before closure. The completed unit was fastened to the syringe adaptor plate by use of tapped holes provided for this purpose in the delivery end plate.

Experience has shown that, with a 1% solution, satisfactory operation results if the thermocouple embedded as described indicates a temperature of about 65 C. Voltage and current readings taken under these conditions show that only about 10 watts of electrical heat are required to keep the 50 cc syringe full of anesthetic solution at the required temperature. To reduce shock hazard, the main line supply voltage to the syringe heater is limited to 24 volts AC.

Some form of adapter is required to fasten the syringe heater assembly to allow the syringe to be operated by the pump. This was accomplished by simple aluminum fittings that did not require modification to the pump itself.
NOTE: AFTER ASSEMBLY, UNIT IS POURED FULL OF RTV SILASTIC FOR INSULATION

END PLATE

CENTER TUBE (AL)

NICHROME HEATER ELEMENT

END PLATE (PLASTIC)

ID TO SUIT SYRINGE

BAKELITE INSULATING SHEATH EPOXIED TO CENTER TUBE

THIS DIA TO SUIT SYRINGE CONNECTOR

SYRINGE

ELECTRICAL CONNECTOR

1/16 TO SUIT SYRINGE BARREL

COVER - 1/16 WALL AL

Figure 1. Syringe Heating Device

Approved for Public Release
SECTION IV
CATHETER HEATING

From a practical standpoint, any means of supplying sufficient heat to the contents of the catheter would be acceptable. However, electrical heating seemed to offer the best solution in terms of bulk, close control, and convenience. The electrically heated catheter is shown in figure 2.

Basically, the unit consists of a piece of Teflon tubing (approximating a number 9 French catheter) which in turn is coaxially surrounded by a commercially available prewound nichrome wire heater coil. In order to avoid intercoil shorting, the length of the coil is cut to allow the turns to be spread apart when stretched the length of the catheter.

Fluid connections to the ends of the catheter are accomplished by introducing the catheter completely through the center holes of the end pieces. The catheter is then fixed at either end by cementing it to the end terminations with epoxy. Following this operation, standard commercial compression fittings with ferrule and gaskets removed are screwed into the threaded holes provided in the end fittings, the excess catheter material is then trimmed off as it extends into the fittings.

Connections to the ends of the electrical coil are made by feeding the wire into angled holes drilled in the plastic end terminations, electrical continuity being affected by threaded brass terminals that clamp the ends of the wire and are provided to allow the installation of a thermocouple (reading catheter wall temperature) in the delivery end fitting of the catheter.

To provide some mechanical strength to relieve the heater coil and catheter of tensile loads, and to provide electrical and thermal insulation of the heater catheter assembly, the entire length of the assembly is shrouded by Teflon chemical tubing having an inside diameter of 6.3 mm (0.25 inch). The Teflon tubing slips over bosses on each end fitting and is held in place by split circular screw clamps. The shroud must be installed before installing the final end fitting.

In the interest of being able to disassemble the unit should repairs be necessary, some of the earlier models used standard Tuffy-Borst compression fittings to trap the catheter in each end fitting instead of cementing the fittings to the catheter as described above. This method resulted in such distortion of the catheter lumen as to completely restrict flow occasionally, owing to the rapid precipitation of chloralose at the site of restriction.

Experience has shown that, under normal room conditions, the heat requirements amount to about 1 watt per centimeter of catheter length. As with the syringe heater, the supply voltage is limited to 24 volts AC.
Figure 2. Heated Catheter
SECTION V
CONCLUSIONS

It has been shown that a practical, trouble-free system for the continuous infusion of chloralose is practical using devices of simple design composed of easily available materials. The system has been shown to overcome the usual difficulties encountered with the administration of this agent, rendering its use, where indicated, much less of a problem than experienced heretofore.
A SYSTEM FOR THE CONTINUOUS INFUSION OF ALPHA-CHLORALOSE ANESTHETIC

Final report, December 1966 - May 1966

Van Patten, Robert E.

Distribution of this document is unlimited.

The development of a system designed to permit semiautomatic and continuous infusion of the anesthetic agent alpha-chloralose to dogs is described. The apparatus was developed for use in studies of cardiovascular and renal functions under various environmental conditions. The device has proved to be practical and trouble-free and the simple design uses easily available materials.
Continuous infusion system
Alpha-chloralose infusion device
Temperature control-syringe
Temperature control-catheter
Cardiovascular and renal functions
Dogs

INSTRUCTIONS

1. ORIGINATING ACTIVITY: Enter the name and address of the contractor, subcontractor, grantee, Department of Defense activity or other organization (corporate entity) issuing the report.

2. REPORT SECURITY CLASSIFICATION: Enter the over-all security classification of the report. Indicate whether "Restricted Data" is included. Marking is to be in accordance with appropriate security regulations.

3. GROUP: Automatic downgrading is specified in DoD Directive 5200.10 and Armed Forces Industrial Manual. Enter the group number. Also, when applicable, show that optional markings have been used for Group 3 and Group 4 as authorized.

4. REPORT TITLE: Enter the complete report title in all capital letters. Titles on all reports should be unclassified. If a meaningful title cannot be selected without classification, show title classification in all capitals in parenthesis immediately following the title.

5. DESCRIPTIVE NOTES: If appropriate, enter the type of report, e.g., interim, progress, summary, annual, final. Give the inclusive date when a specific reporting period is covered.

6. AUTHORS: Enter the name(s) of author(s) as shown on the report. Enter last name, first name, middle initial. If military, show rank and branch of service. The name of the principal author is to be an absolute minimum requirement.

7. REPORT DATE: Enter the date of the report as day, month, year, or month, year. If more than one date appears on the report, use date of publication.

8. TOTAL NUMBER OF PAGES: The total page count should follow normal pagination procedures, i.e., enter the number of pages containing information.

9. NUMBER OF REFERENCES: Enter the total number of references cited in the report.

10. CONTRACT OR GRANT NUMBER: If appropriate, enter the applicable number(s) of the contract or grant under which the report was written.

11. W/ & R. PROJECT NUMBER: Enter the appropriate project number for the document. If project number, subproject number, review number, task number, etc., is involved, enter complete number.

12. INDICATION OF NOTIFICATION: Enter the official project number and title of the document will be identified and one will not be classified as "Restricted Data." The number must not be visible to this report.

13. OTHER REPORT NUMBER(S): If the report has been identified as unsuitable for classified handling, leave this section blank.

14. AVAILABILITY LIMITATION NOTICES: Enter any limitations on further dissemination of the report, other than those imposed by security classification, using standard statements such as:

   (1) "Qualified recipients may obtain copies of this report from DDC.

   (2) "Foreign announcement and dissemination of this report by DDC is not authorized.

   (3) "U. S. Government agencies may obtain copies of this report directly from DDC. Other qualified DDC users shall request through"

   (4) "U. S. military agencies may obtain copies of this report directly from DDC. Other qualified users shall request through"

   (5) "All distribution of this report is controlled. Qualified DDC users shall request through"

If the report has been assigned to the Office of Technical Services, Department of Commerce, for sale to the public, indicate this fact and enter the price, if known.

11. SUPPLEMENTARY NOTES: Use for additional explanatory notes.

12. SPONSORING MILITARY ACTIVITY: Enter the name of the departmental project office or laboratory sponsoring (paying for) the research and development. Include address.

13. ABSTRACT: Enter a short, concise statement of the purpose and contents of the report. It should give a general idea of the findings and conclusions. The statement should be non-classified.

It is highly desirable that the abstract of classified reports be unclassified. Each paragraph of the abstract shall end with an indication of the military security classification of the information in the paragraph. Represented as (TS), (S), (C), or (F) in the abstract. The unclassified paragraph shall be blank.

14. KEY WORDS: Key words are technically meaningful terms or short phrases that characterize a report and may be used as index entries for cataloging the report. Key words must be selected so that no security classification is required. Index words should be selected from official classified index word lists, national directories or other similar sources (e.g., NASA, DOD, NIC) and placed in alphabetical order. They may be used as index entries for cataloging the report.

There is no limitation on the length of the abstract. However, the suggested length is from 150 to 225 words.

15. KEY WORDS: Key words are technically meaningful terms or short phrases that characterize a report and may be used as index entries for cataloging the report. Key words must be selected so that no security classification is required. Index words should be selected from official classified index word lists, national directories or other similar sources (e.g., NASA, DOD, NIC) and placed in alphabetical order. They may be used as index entries for cataloging the report.

There is no limitation on the length of the abstract. However, the suggested length is from 150 to 225 words.